Genflow Biosciences appoints ON365 as investor relations adviser

Genflow Biosciences Plc has appointed ON365 Partners Inc. as its investor relations adviser with immediate effect. ON365 replaces Harbor Access, which had previously supported the company’s investor relations activities.

#ON365 appointment and investor engagement

ON365 is described as an investor relations and strategic advisory firm serving the healthcare and life sciences sectors. Its work includes capital markets advice, engagement with investors and corporate communications support for publicly listed companies.

Genflow said it believes ON365’s healthcare and life sciences focus, along with its North American investor network, will support the company’s communications with institutional and retail investors across its listings. Genflow is listed on LSE:GENF and OTCQB:GENFF.

The company thanked Harbor Access for its contribution to Genflow’s investor relations programme.

#Genflow’s SIRT6 platform

Genflow is developing gene therapies for age-related diseases. Its lead compound, GF-1002, uses a centenarian variant of the SIRT6 gene, and the company says the programme has produced promising preclinical results.

In comments included with the announcement, Chief Executive Officer Dr. Eric Leire said the company is moving its SIRT6 platform from preclinical work into a broader body of clinical, regulatory and commercial evidence. He said ON365’s healthcare and life sciences experience and North American investor relationships would help Genflow communicate with a wider investment audience.

#Clinical development programmes

Genflow’s proof-of-concept clinical trial assessing its SIRT6-centenarian gene therapy in aged dogs began in March 2025.

The company also plans a clinical trial examining the potential benefits of GF-1002 in treating MASH, which the announcement describes as the most prevalent chronic liver disease for which there are no effective treatments.

#Company background and forward-looking statements

Founded in 2020, Genflow is headquartered in the UK and has research and development facilities in Belgium. The company describes its work as focused on gene therapies for age-related diseases, with a goal of promoting longer and healthier lives while addressing the financial, emotional and social effects of an aging global population.

Genflow’s announcement states that forward-looking statements are based on current expectations and assumptions and are subject to uncertainties, risks and changing circumstances. It cautions that actual financial condition, operating results and performance may differ materially from those statements. The company identifies political, economic, social, business, technological, competitive, market and regulatory conditions among factors that could contribute to differences.

#Key Takeaways

Genflow Biosciences appointed ON365 Partners Inc. as its investor relations adviser with immediate effect.
ON365 succeeds Harbor Access and focuses on healthcare and life sciences companies.
Genflow said ON365’s North American network will support engagement with institutional and retail investors.
The company’s lead programme, GF-1002, uses a centenarian SIRT6 gene variant and has reported promising preclinical results.
A proof-of-concept trial in aged dogs began in March 2025, while another planned trial will examine GF-1002 in MASH.

Original source: Read original article

Frequently Asked Questions

Genflow Biosciences Plc has announced the appointment of ON365 Partners Inc. as its investor relations adviser, with immediate effect. ON365 succeeds Harbor Access, which had supported the Company’s investor relations activities to date.

The source describes ON365 as a specialist investor relations and strategic advisory firm focused on the healthcare and life sciences sector. Its services include capital markets counsel, investor engagement and corporate communications support for publicly listed companies.

Genflow says it believes ON365’s sector focus and North American investor network will support the Company as it advances its centenarian SIRT6 gene therapy platform and broadens dialogue with institutional and retail investors across its listings. The source does not provide financial terms for the appointment.

The source identifies Genflow Biosciences Plc as listed on LSE:GENF and OTCQB:GENFF.

The source says Genflow’s lead compound, GF-1002, works through delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results. The Chief Executive Officer described the platform as moving from preclinical promise into a growing body of clinical, regulatory and commercial evidence. The source does not provide further clinical, regulatory or commercial results in this announcement.

Genflow’s proof-of-concept clinical trial evaluating its SIRT6-centenarian gene therapy in aged dogs began in March 2025. The source also says another clinical trial will explore the potential benefits of GF-1002 in treating MASH, which it describes as the most prevalent chronic liver disease for which there is no effective treatments.

The source says Genflow Biosciences was founded in 2020, is headquartered in the UK and has R&D facilities in Belgium. It describes the Company as a biotechnology company pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional and social impacts of a fast-growing aging global population.

The announcement states that forward-looking statements are based on current expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. It says actual financial condition, results of operations and performance may differ materially from those statements, and identifies political, economic, social, business, technological, competitive, market and regulatory conditions among factors that could cause differences.